|
Press Releases |
|
|
|
Thursday, May 23, 2024 |
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
Wednesday, May 22, 2024 |
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
Wednesday, May 15, 2024 |
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
Monday, May 13, 2024 |
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
Thursday, April 18, 2024 |
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
Wednesday, April 17, 2024 |
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
Wednesday, April 3, 2024 |
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
Monday, April 1, 2024 |
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
Friday, March 29, 2024 |
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Academic Labs, the Pioneering Crypto Platform Achieves a $300M at Its ICO
Nov 14, 2024 09:00 HKT/SGT
|
|
|
Blueberry Rebrand Reflects Exciting New Era for the Forex Company
Nov 14, 2024 09:00 HKT/SGT
|
|
|
ULVAC Launches Oil Rotary Vacuum Pump Gv135
Nov 14, 2024 10:00 JST
|
|
|
Femto Technologies Announces Third Quarter 2024 Financial Results
Nov 14, 2024 07:00 HKT/SGT
|
|
|
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Nov 13, 2024 23:00 HKT/SGT
|
|
|
Interview with Spectral's Sean Brehm on DQLDB the Vogon Cloud
Nov 13, 2024 20:40 HKT/SGT
|
|
|
Spectral Releases its Quantum Bridge Strategy for a Decentralized, Sustainable Future Using Quantum-Resilient Edge Computing
Nov 13, 2024 20:32 HKT/SGT
|
|
|
COP29: PLN Encourages Global Collaboration for Energy Transition Towards Sustainable Energy Self-Sufficiency
Nov 13, 2024 20:00 HKT/SGT
|
|
|
Academic Labs Secures $3.2M to Revolutionize Educational Resource Sharing with Web3, $AAX Listing by 11th Nov 2024
Nov 13, 2024 17:00 HKT/SGT
|
|
|
The China-ASEAN "Gen Z" Youth Festival and Cultural Exchange Activity Officially Launched
Nov 13, 2024 17:00 HKT/SGT
|
|
|
MHI Publishes MHI REPORT 2024
Nov 13, 2024 16:52 JST
|
|
|
APTEXPO 2024 Kicks Off with Key Fashion and Supply Chain Leaders Sparking Innovation on Day One
Nov 13, 2024 14:00 HKT/SGT
|
|
|
analytica Vietnam Expands for 2025 with Addition of New Hall
Nov 13, 2024 13:26 HKT/SGT
|
|
|
SoftBank Corp. and Fujitsu Strengthen Partnership for Realization of AI-RAN Commercialization
Nov 13, 2024 12:38 JST
|
|
|
Predictive Heart Monitoring Startup, GPx, Secures New Investment From NEC X; Joins Elev X! Boost Venture Studio Program
Nov 13, 2024 12:05 JST
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|